Pancreas disorders

Exocrine Pancreatic Insufficiency (EPI) Market Insights, Epidemiology and Market Forecast 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 8, 2021
Health, Pharmaceutical, Pancreas disorders, EPI, Insufficiency, Exocrine pancreatic insufficiency, Pancreas, Clinical medicine

The "Exocrine Pancreatic Insufficiency (EPI) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Exocrine Pancreatic Insufficiency (EPI) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • This 'Exocrine Pancreatic Insufficiency (EPI) -Market Insights, Epidemiology and Market Forecast- 2030' report delivers an in-depth understanding of the Exocrine Pancreatic Insufficiency (EPI), historical and forecasted epidemiology as well as the Exocrine Pancreatic Insufficiency (EPI) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
  • The drug chapter segment of the Exocrine Pancreatic Insufficiency (EPI) report encloses the detailed analysis of Exocrine Pancreatic Insufficiency (EPI) marketed drugs and mid and late stage pipeline drugs.
  • The Exocrine Pancreatic Insufficiency (EPI) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted Exocrine Pancreatic Insufficiency (EPI) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.

Exocrine Pancreatic Insufficiency (EPI) Epidemiology Forecast Report 2021-2030 - ResearchAndMarkets.com

Retrieved on: 
Monday, July 5, 2021
Health, Other Health, Pancreas disorders, Medical specialties, Insufficiency, EPI, Exocrine pancreatic insufficiency, Pancreas

The "Exocrine Pancreatic Insufficiency (EPI) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Exocrine Pancreatic Insufficiency (EPI) - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
  • The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalence of Causative Indications of EPI and Prevalence of Exocrine Pancreatic Insufficiency scenario of Exocrine Pancreatic Insufficiency (EPI) in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
  • The report covers the descriptive overview of Exocrine Pancreatic Insufficiency (EPI), explaining its causes, signs and symptoms, pathophysiology.
  • Out of the above-mentioned countries, which country would have the highest prevalent population of Exocrine Pancreatic Insufficiency (EPI) during the forecast period (2020-2030)?

Aimmune Launches the First Real-World Registry Study for Patients with Chronic Pancreatitis

Retrieved on: 
Tuesday, June 8, 2021
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Fitness & Nutrition, Clinical trials, Pancreas disorders, Medical specialties, Chronic pancreatitis, Pancreatitis, Medicine, Clinical medicine, the PACT-CP - Patient-Centric Chronic Pancreatitis Registry Study, Aimmune, Nestlé Health Science, THE PACT-CP - PATIENT-CENTRIC CHRONIC PANCREATITIS REGISTRY STUDY, AIMMUNE, NESTLé HEALTH SCIENCE

Studies such as PACT-CP will be invaluable in improving the understanding and treatment of complex disorders such as chronic pancreatitis."

Key Points: 
  • Studies such as PACT-CP will be invaluable in improving the understanding and treatment of complex disorders such as chronic pancreatitis."
  • The study was designed using input from patients and expert advisors and will track approximately 400 patients at 20 gastroenterology sites across the United States.
  • The PACT-CP Registry study is a prospective, non-interventional research study for individuals diagnosed with EPI due to CP under the care of a gastroenterologist.
  • AIMMUNE and AIMMUNE THERAPEUTICS are trademarks of Aimmune Therapeutics, Inc.
    View source version on businesswire.com: https://www.businesswire.com/news/home/20210608005124/en/

Eloxx Pharmaceuticals Announces Funding Award from Cystic Fibrosis Foundation for Development of Ribosome Modulating Agents

Retrieved on: 
Thursday, May 27, 2021
Medical specialties, Pancreas disorders, Channelopathies, Cystic fibrosis, Branches of biology, Cystic Fibrosis Foundation, Ribosome, Eukaryotic ribosome, Anatomy

We are honored to receive this funding from the Cystic Fibrosis Foundation in our ongoing commitment to identify and develop new treatments for CF.

Key Points: 
  • We are honored to receive this funding from the Cystic Fibrosis Foundation in our ongoing commitment to identify and develop new treatments for CF.
  • We have tremendous confidence in the potential of RMAs designed with TURBO-ZMto treat rare genetic diseases, said Sumit Aggarwal, President and Chief Executive Officer.
  • Mr. Aggarwal continued, In addition, the development of a Ribosome Modulating Agent for the treatment of CF with support from the Cystic Fibrosis Foundation complements our ongoing ELX-02 program, currently in Phase 2 clinical trials.
  • Eloxx Pharmaceuticals, Inc.is engaged in the science of ribosome modulation, leveraging both its innovative TURBO-ZMchemistry technology platform in an effort to develop novel Ribosome Modulating Agents (RMAs) and its library of Eukaryotic Ribosome Selective Glycosides (ERSGs).

Global Pancreatic Cancer Markets, Epidemiology and Patient Flow Report 2021 with Forecast to 2035 - ResearchAndMarkets.com

Retrieved on: 
Friday, May 21, 2021
Health, Oncology, Gastrointestinal cancer, Pancreatic cancer, Epidemiology of cancer, Cancer, Pancreas disorders, Medical specialties, Clinical medicine

b'The "Global Pancreatic Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2021, provides Pancreatic Cancer epidemiology, demographics, and patient flow.

Key Points: 
  • b'The "Global Pancreatic Cancer Epidemiology and Patient Flow - 2021" report has been added to ResearchAndMarkets.com\'s offering.\nGlobal Pancreatic Cancer Epidemiology and Patient Flow Analysis - 2021, provides Pancreatic Cancer epidemiology, demographics, and patient flow.
  • The data is presented by Pharma G7 countries including the US, France, Spain, Italy, UK, Japan.\nThe research provides population data to characterize Pancreatic Cancer patients, history of the disease at the population level (Pancreatic Cancer prevalence, Pancreatic Cancer incidence) and at the clinical level (from diagnosis to treated patients).
  • It also helps to identify patient sub-groups (age, gender, sub-groups) to understand targeted population for research and development, commercialization.\nDemographics: Pancreatic Cancer patients by age group, gender\nThe data from this research will help executives:\nEstablish basis for Pancreatic Cancer market sizing, assessing market potential, and developing drug forecast models\nIdentify Pancreatic Cancer patients segments through age groups, gender, and disease sub-types\nEvaluate Pancreatic Cancer market opportunities, identify target patient population\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210521005157/en/\n'

Outlook on the Medical Enzyme Technology Global Market to 2028 - Rising Production of Biopharmaceutical Products Presents Opportunities - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021
Biotechnology, Pharmaceutical, Health, Branches of biology, Medical specialties, Biology, Medical genetics, Metabolism, Pancreas disorders, Abdominal pain, Pancreatitis, Jaundice, Metabolic disorder, Aspartate transaminase, Neurodegeneration

Abnormalities in enzyme metabolism system leads to many metabolic diseases.

Key Points: 
  • Abnormalities in enzyme metabolism system leads to many metabolic diseases.
  • Many enzymes are being widely used in the clinical examination as a specific disease marker.
  • Enzymes are the preferred markers in various disease states such as myocardial infarction, jaundice, pancreatitis, cancer, and neurodegenerative disorders.
  • However, the market for normothermic machine perfusion is estimated to grow at a higher CAGR of 4.4% during the forecast period.\nThe medical enzyme technology market, by application, is segmented into disease treatment, diagnostic tools, biomedical research, and others.

SpliSense Secures $28.5 Million in Series B Financing

Retrieved on: 
Thursday, May 13, 2021
Branches of biology, Biology, Cystic fibrosis, Pancreas disorders, Cystic fibrosis transmembrane conductance regulator, Messenger RNA, Batsheva Kerem

b'JERUSALEM, May 13, 2021 /PRNewswire/ -- SpliSense , a biopharmaceutical company developing transformative mRNA-altering therapies for cystic fibrosis (CF) and other genetic pulmonary diseases, today announced that it has closed a $28.5 million Series B funding round.

Key Points: 
  • b'JERUSALEM, May 13, 2021 /PRNewswire/ -- SpliSense , a biopharmaceutical company developing transformative mRNA-altering therapies for cystic fibrosis (CF) and other genetic pulmonary diseases, today announced that it has closed a $28.5 million Series B funding round.
  • SpliSense utilizes short, precisely targeted proprietary RNA stretches called ASOs to correct various mutations in the CFTR mRNA.
  • Nissim Darvish, MD, Chairman of the Board, SpliSense, "SpliSense couples Prof. Kerem\'s pioneering research on the genetic underpinnings of CF together with a strong track record in developing ASO therapies and inhaled treatments.
  • SpliSense\' pipeline includes innovative therapies in various development stages, from discovery to IND enabling studies.

AzurRx BioPharma Announces Positive Interim Data in Phase 2 Clinical Trial of MS1819 in Combination with PERT in the Treatment of Cystic Fibrosis Patients with Severe Exocrine Pancreatic Insufficiency

Retrieved on: 
Thursday, May 13, 2021
Pancreas disorders, Medical specialties, Organ systems, Clinical medicine, Exocrine pancreatic insufficiency, Chronic pancreatitis, Pancreatitis, Cystic fibrosis, Insufficiency

We expect to report full topline results from all 20 patients enrolled in the trial in the second quarter of 2021.\xe2\x80\x9d\nDr.

Key Points: 
  • We expect to report full topline results from all 20 patients enrolled in the trial in the second quarter of 2021.\xe2\x80\x9d\nDr.
  • Based on the clinical evidence from the combination trial to-date, we have been able to improve the nutritional status of the severe EPI patients who need the most help.
  • It turns out that the patients with the lowest baseline CFAs had the largest improvements in CFA in the study.
  • The lead therapeutic candidate is\xc2\xa0MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis,\xc2\xa0currently in two Phase 2 clinical trials.

AzurRx BioPharma Receives Approximately $550K for its 2020 CIR (French Research Tax Credit)

Retrieved on: 
Wednesday, May 12, 2021
Pancreas disorders, Medical specialties, Organ systems, Clinical medicine, Exocrine pancreatic insufficiency, Chronic pancreatitis, Pancreatitis, Cystic fibrosis, Insufficiency, Pancreas, Pancreatic disease

These funds have enabled us to successfully run the European arms of our two Phase 2 MS1819 clinical trials - despite the challenges posed by the COVID epidemic.

Key Points: 
  • These funds have enabled us to successfully run the European arms of our two Phase 2 MS1819 clinical trials - despite the challenges posed by the COVID epidemic.
  • It is particularly adapted to the needs of small and medium-sized enterprises.\nAzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
  • The lead therapeutic drug candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
  • For more information visit www.azurrx.com .\nThis press release may contain certain statements relating to future results which are forward-looking statements.

AzurRx BioPharma Announces Participation in the Q2 Virtual Investor Summit

Retrieved on: 
Tuesday, May 11, 2021
Pancreas disorders, Medical specialties, Organ systems, Clinical medicine, Exocrine pancreatic insufficiency, Chronic pancreatitis, Pancreatitis, Cystic fibrosis, Pancreas, Lipase, Insufficiency, Anthera Pharmaceuticals

b'AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.

Key Points: 
  • b'AzurRx BioPharma, Inc. (NASDAQ: AZRX) is a clinical stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases.
  • The Company has a pipeline of three gut-restricted GI assets.
  • The lead therapeutic candidate is MS1819, a recombinant lipase for the treatment of exocrine pancreatic insufficiency (EPI) in patients with cystic fibrosis and chronic pancreatitis.
  • The Company is headquartered in Delray Beach, Florida with clinical operations in Hayward, California.